SCHEMBL6771880

SCHEMBL6771880

C=CCOCc1cc(C=O)ccc1OCC=C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.43
CYP1A2 P05177 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HPGD P15428 2/20 0.43
POLB P06746 1/20 0.43
FDPS P14324 1/20 0.40
MAPK1 P28482 1/20 0.39
LMNA P02545 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
TSHR P16473 2/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 3/20 0.38
HTT P42858 2/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4E B2RXH2 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8534293 0.84 KDM4E (0.48) ALDH1A1CYP1A2MEN1KMT2AHPGD
SCHEMBL3464451 0.80 FDPS (0.54) ALDH1A1MEN1KMT2AHPGDFDPS
SCHEMBL19251015 0.79 MAOA (0.46) ALDH1A1MEN1KMT2AFDPSTSHR
SCHEMBL31247739 0.76 FDPS (0.42) ALDH1A1MEN1KMT2AHPGDFDPS
SCHEMBL27804316 0.76 FDPS (0.42) ALDH1A1MEN1KMT2AHPGDFDPS
SCHEMBL4617044 0.76 TSHR (0.44) ALDH1A1MEN1KMT2AHPGDFDPS
SCHEMBL18095839 0.76 ALDH1A1 (0.49) ALDH1A1MEN1KMT2AHPGDPOLB
SCHEMBL1422917 0.76 ALDH1A1 (0.57) ALDH1A1HPGDFDPSMAPK1TSHR
SCHEMBL944430 0.76 ALDH1A1 (0.48) ALDH1A1CYP1A2HPGDFDPSMAPK1
SCHEMBL1396839 0.75 FDPS (0.71) ALDH1A1MEN1KMT2AHPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6683095-B2 ANTICARCINOGENIC AGENTS; ANTIPROLIFERATION AGENTS LG LIFE SCIENCES LTD. (KR) 2004-01-27 US disclosed
US-20030125356-A1 Cdk inhibitors having 3-hydroxychromen-4-one structure LG LIFE SCIENCES LTD. (KR) 2003-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125356-A1 Cdk inhibitors having 3-hydroxychromen-4-one structure CDK4, CDK3, CDK6 ALDH1A1 1157/4885CYP1A2 1201/4885MEN1 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.